52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Geert R. D'Haens  1     Remo Panaccione  2     Julian Panés  3     Tadakazu Hisamatsu  4     Peter Bossuyt  5     Silvio Danese  6     Ezequiel Neimark  7     Alexandra Song  7     Xiaomei Liao  7     Kori Wallace  7     Javier Zambrano  7     Rachel Duan  7     Kristina Kligys  7     Marla C. Dubinsky  8    
1 AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands
2 University of Calgary, Calgary, Canada
3 Hospital Clínic Barcelona, Barcelona, Spain
4 Kyorin University School of Medicine, Tokyo, Japan
5 Imelda General Hospital, Bonheiden, Belgium
6 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
7 AbbVie Inc., North Chicago, United States
8 Mount Sinai Hospital, Mount Sinai, New York City, United States

Topic
IBD, Nurses, Primary Care

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing